Compare
Phathom Pharmaceuticals, Inc. vs Maravai Lifesciences Holdings, Inc. vs Puma Biotechnology, Inc. vs Akebia Therapeutics, Inc.
| Latest fiscal year | Phathom Pharmaceuticals, Inc. PHAT | Maravai Lifesciences Holdings, Inc. MRVI | Puma Biotechnology, Inc. PBYI | Akebia Therapeutics, Inc. AKBA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $175.11M | $185.74M | $228.37M | $236.20M |
| Revenue growth (YoY) | +216.9% | -28.3% | -0.9% | +47.5% |
| Gross margin | 87.1% | 18.3% | 74.5% (computed) | 83.3% (computed) |
| Operating margin | -91.4% | -115.9% | 16.3% | 9.9% |
| Net margin | -126.3% | -70.4% | 13.6% | -2.3% |
| Net income | -$221.25M | -$130.77M | $31.11M | -$5.34M |
| EPS (Diluted) | -$3.03 | -$0.90 | $0.61 | -$0.02 |
| Operating cash flow | -$166.78M | -$57.57M | $41.80M | $67.99M |
| Free cash flow | -$167.00M | -$70.72M | $41.73M | $67.70M |
| Cash & equivalents | $129.97M | $216.89M | $29.64M | $184.84M |
| Total assets | $259.15M | $770.58M | $216.30M | $376.56M |
| Total liabilities | $697.32M | $397.87M | $85.96M | $343.95M |
| Shareholders' equity | -$438.17M | $212.38M | $130.34M | $32.61M |
| Return on year-end equity | n/a | -61.6% | 23.9% | -16.4% |
| Shares outstanding | 71.42M | n/a | 50.41M | 265.42M |
Revenue, most recent five fiscal years
| Fiscal year | Phathom Pharmaceuticals, Inc. | Maravai Lifesciences Holdings, Inc. | Puma Biotechnology, Inc. | Akebia Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $175.11M Ended 2025-12-31 | $185.74M Ended 2025-12-31 | $228.37M Ended 2025-12-31 | $236.20M Ended 2025-12-31 |
| 1 year earlier | $55.25M Ended 2024-12-31 | $259.19M Ended 2024-12-31 | $230.47M Ended 2024-12-31 | $160.18M Ended 2024-12-31 |
| 2 years earlier | $682.0K Ended 2023-12-31 | $288.94M Ended 2023-12-31 | $235.64M Ended 2023-12-31 | $194.62M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $883.00M Ended 2022-12-31 | $228.03M Ended 2022-12-31 | $292.48M Ended 2022-12-31 |
| 4 years earlier | n/a | $799.24M Ended 2021-12-31 | $253.16M Ended 2021-12-31 | $211.65M Ended 2021-12-31 |